A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms NICOLAS
- 04 Dec 2017 Status changed from active, no longer recruiting to recruiting.
- 21 Aug 2017 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 21 Aug 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2020.